Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors

A compound of formula (I):

• wherein
• A is a fused 5-membered heteroaryl ring substituted by —(CH2)maryl or —(CH2)mheteroaryl wherein the aryl or heteroaryl is optionally substituted by one or more substituents independently selected from oxo, C1-6alkyl, halogen, —CN, trifluoromethyl, —OR3, —(CH2)nCO2R3, —NR3R4, —(CH2)nCONR3R4, —NHCOR3, —SO2NR3R4, —NHSO2R3 and —S(O)pR3, and
• A is optionally further substituted by one substituent selected from —OR5, halogen, trifluoromethyl, —CN, —CO2R5 and C1-6alkyl optionally substituted by hydroxy;
• R1 is selected from methyl and chloro;
• R2 is selected from —NH—CO—R6 and —CO—NH—(CH2)q—R7;
• R3 is selected from hydrogen, —(CH2)r—C3-7cycloalkyl, —(CH2)rheterocyclyl, —(CH2)raryl, and C1-6alkyl optionally substituted by up to two substituents independently selected from —OR8 and —NR8R9,
• R4 is selected from hydrogen and C1-6alkyl, or
• R3 and R4, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R10;
• R5 is selected from hydrogen and C1-6alkyl;
• R6 is selected from hydrogen, C1-6alkyl, —(CH2)q—C3-7cycloalkyl, trifluoromethyl, —(CH2)sheteroaryl optionally substituted by R11 and/or R12, and —(CH2)sphenyl optionally substituted by R11 and/or R12;
• R7 is selected from hydrogen, C1-6alkyl, C3-7cycloalkyl, —CONHR13, phenyl optionally substituted by R11 and/or R12, and heteroaryl optionally substituted by R11 and/or R12;
• R8 and R9 are each independently selected from hydrogen and C1-6alkyl;
• R10 is selected from hydrogen and methyl;
• R11 is selected from C1-6alkyl, C1-6alkoxy, —(CH2)q—C3-7cycloalkyl, —CONR13R14, —NHCOR14, halogen, —CN, —(CH2)tNR15R16, trifluoromethyl, phenyl optionally substituted by one or more R12 groups, and heteroaryl optionally substituted by one or more R12 groups;
• R12 is selected from C1-6alkyl, C1-6alkoxy, halogen, trifluoromethyl, and —(CH2)tNR15R16;
• R13 and R14 are each independently selected from hydrogen and C1-6alkyl, or
• R13 and R14, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R10, wherein the ring may be substituted by up to two C1-6alkyl groups;
• R15 is selected from hydrogen, C1-6alkyl and —(CH2)q—C3-7cycloalkyl optionally substituted by C1-6alkyl,
• R16 is selected from hydrogen and C1-6alkyl, or
• R15 and R16, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R10;
• X and Y are each independently selected from hydrogen, methyl and halogen;
• m, n, p and q are each independently selected from 0, 1 and 2;
• r and s are each independently selected from 0 and 1;
• and
• t is selected from 0, 1, 2 and 3;
• with the proviso that when A is substituted by —(CH2)mheteroaryl and m is 0, the —(CH2)mheteroaryl group is not a 5-membered heteroaryl ring optionally substituted by C1-2alkyl;
• or a pharmaceutically acceptable derivative thereof.